Small Cap Voice

Progressive Care Inc. (OTC: RXMD), through its subsidiaries, is a Florida technology and health services organization that provides prescription pharmaceuticals, compounded medications, provider of tele-pharmacy services, the sale of anti-retroviral medications, medication therapy management (MTM), the supply of prescription medications to long-term care facilities, and health practice risk management.

“COVID-19 has dramatically changed the economic landscape of all industries and few have been able to adapt and lead in the manner we have,” stated S. Parikh Mars, CEO. “We are looking forward to discussing the financial performance of the Company as well as all of the initiatives currently underway.”

Progressive Care Inc. (RXMD) (“Progressive Care” or the “Company”), a personalized healthcare services and technology company, is very pleased to announce that the Company has obtained the immediate capacity to market and distribute rapid-results antibody test kits (COVID-19 IgG/IgM) registered through the FDA under its Emergency Use Authorization (“EUA”) guidelines for conducting SARS-CoV-2 antibody presence and COVID-19 infection diagnosis testing.

The COVID-19 Rapid Antibody Test Kits will be made available through our pharmacies and national e-commerce platform to healthcare providers for further administration to their patients. The antibody test kits are designed for use by a medical professional through the collection of a small fingertip blood sample, with results available within 15 minutes. A positive result indicates the need for an additional serological test to confirm.

“As major operations begin to reopen in our communities, experts believe diagnostic and antibody testing will be crucial in identifying vulnerabilities and creating safer and more productive public living conditions,” comments S. Parikh Mars, CEO of Progressive Care. “We believe it is imperative that we provide the public health resources necessary to stem the tide of this pandemic.”

Phase One economic reopening is currently underway in Florida, where Progressive Care is based. As businesses reopen, rapid results testing is widely considered to be an essential resource. Organizations and their employees consistently express a strong desire to know if they have been exposed to SARS-CoV-2 and therefore acquired antibodies for, and potential immunity to, the virus that causes the COVID-19 disease. Antibody testing is not designed as a diagnostic tool, but can be valuable in determining the prevalence of exposure and/or recovery within a community. Such information can help public health officials, community leaders, employers, and citizens make decisions about potential risk factors, containment, and mitigation strategies.

The Company is preparing to conduct a COVID-19 antibody case study in South Florida to help guide health preservation protocols and public discourse about the pandemic.

“We are truly grateful for this opportunity to help our community control the spread and flatten the curve as we shed further light on this virus and its confoundingly broad physiological effects and societal implications,” continued Mars. “We are excited to develop new and growing relationships with organizations and healthcare providers in our marketplace interested in partnering with us to deliver this powerful new solution.”

Interview with Larry Diamond, the CEO of Mitesco, Inc. (OTCQB: MITI) and Julie R. Smith, President & Chief Operating Officer.

Larry Diamond, the CEO of Mitesco, Inc. (OTCQB: MITI) (the “Company” or “Mitesco”) and Julie R. Smith, President & Chief Operating Officer of the Company, called in to SmallCapVoice.com, Inc. to discuss recent news and moves by the Company since our last interview with the Company in December 2019. Smith outlined the reason for the recently announced name and ticker symbol change, while Diamond provided an overview of the the details of its general solicitation private placement offering (“Offering”) solely to accredited investors under Rule 506(c) of Regulation D. Diamond went on to discuss the direction of Mitesco going forward and how the Company will follow a similar path as MTBC, Inc. (NasdaqGS: MTBC).

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $1,500 from the company on 5-7-2020 for 30 days of Audio Interview and Social Media services.

Interview with Aaron Carpenter CEO of Transact Payments Malta Limited (TPML) and Chris Jackson President of CLOQ

Aaron Carpenter, Chief Executive Officer of Transact Payments Malta Limited (TPML) and Chris Jackson, President of Cyberloq Technologies, Inc. (OTC: CLOQ), called in to SmallCapVoice.com to discuss their work together to battle E-commerce payment fraud, the effects of the global pandemic on the protection of personal information from cyber criminals, how CLOQ uses geofencing and multi-factor authentication in real time to stay ahead of their competitors and much more. Long considered a leader in the payments industry, TPML has built its reputation as an expert source of international payment and card solutions and regulatory compliance. The integration of this expertise with CyberloQ’s customizable data security solutions will enable the prevention of online payment fraud within multiple card networks in Europe and beyond. CyberloQ Technologies Inc. (OTC: CLOQ) secures clients’ sensitive data and valuable information with a patented, aggressive and proactive approach. CyberloQ’s advanced authentication algorithms, private blockchain and industry-leading geofencing capabilities give clients complete control of their data for real-time authentication and dedicated fraud protection. For more information, visit https://cyberloq.com/.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $3,500 from a third party on behalf of the issuer on 1-31-2020 for 30 days of service. SmallCapVoice.com, Inc. will receive $2,500 month and a one time payment of 80,000 rule 144 shares from the company for 90 days of service starting on 3-19-2020.

China, China Xiangtai Food Co., Ltd (NASDAQ: PLIN), is a food company primarily engaged in pork processing.

Mr. Xiaohui Wu, the President and Director of China Xiangtai Food, called in to SmallCapVoice.com to go over the business model and outlook for the company. Headquartered in Chongqing, China, China Xiangtai Food Co., Ltd (NASDAQ: PLIN), is a food company primarily engaged in pork processing. The Company’s operations span key sections of the pork processing value chain, including slaughtering, packing, distribution, and wholesale of a variety of fresh pork meat and parts. Primarily focused on pork products, the Company also offers other fresh and processed products, including beef, lamb and poultries. Through its core values, the Company is committed to maintaining the highest standards of food safety, product quality, and sustainability to provide high-quality, nutritious, and tasty food in a responsible manner through its portfolio of trusted brands. For more information, please visit http://ir.plinfood.com/.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $750 from a third party on behalf of the issuer on 4-30-2020 for 30 days of Audio Interview service.

QBIO is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector.

Q BioMed (OTCQB: QBIO) (“the Company”) CEO Denis Corin called in to SmallCapVoice.com to discuss the recent news and events for the Company. Very early on in the coronavirus saga, that would evolve into a global health pandemic, QBIO made a major announcement about the work being done its research partner Mannin Research Inc. The combined efforts of the two companies was to develop a potential adjunct treatment for various infectious diseases like the coronavirus. Recent news highlighted the urgency for the rapid development of novel drugs for the treatment of life-threatening complications caused by COVID-19 and other viral infections. Corin gives an update as well as an overall overview of QBIO’s work in this area.

Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏. Please visit http://www.QBioMed.com and sign up for regular updates.

This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received $875 from the company on 4-28-2020 for 30 days of Audio Interview service.

Cash flow generated from phase one of the Harquahala Mine will fund future exploration on all of the Company's current projects eliminating the need to issue shares to raise capital.